Market capitalization | $141.33m |
Enterprise Value | $122.94m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.14 |
P/S ratio (TTM) P/S ratio | 3.61 |
P/B ratio (TTM) P/B ratio | negative |
Revenue (TTM) Revenue | $39.17m |
EBIT (operating result TTM) EBIT | $-30.67m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
8 Analysts have issued a Nanobiotix - ADR forecast:
8 Analysts have issued a Nanobiotix - ADR forecast:
Jun '24 |
+/-
%
|
||
Revenue | 39 39 |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -29 -29 |
46%
46%
|
EBIT (Operating Income) EBIT | -31 -31 |
45%
45%
|
Net Profit | -36 -36 |
41%
41%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Nanobiotix SA engages in the development of nanoparticle-based technologies for the treatment of cancer. The company's technologies include NanoXray that improves the efficacy of radiation therapy against tumor cells. It also engages in the development of magnetic particles and laser activated nanoparticles for the treatment and diagnosis of cancer. The company was founded by Laurent Lévy and Abdel Kader Boussaha on March 4, 2003 and is headquartered in Paris, France.
Head office | France |
CEO | Laurent Lévy |
Employees | 102 |
Founded | 2003 |
Website | www.nanobiotix.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.